Answer
Yes. Bleeding is its principal safety risk and may occur at the arterial access site or elsewhere; severe bleeding is uncommon but potentially life-threatening.
Sources for this answer
- Kengrexal 50 mg powder for concentrate for solution for injection / infusion. — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.